A Phase 1/2, Randomized, Double-Blind Trial of the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older
Latest Information Update: 03 Jan 2025
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 30 Dec 2024 Planned End Date changed from 23 Jul 2025 to 13 Aug 2025.
- 30 Dec 2024 Planned primary completion date changed from 23 Jul 2025 to 13 Aug 2025.
- 26 Jul 2024 Planned End Date changed from 28 Jul 2025 to 23 Jul 2025.